|
Comparative Trial between Bexxar and Zevalin Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Comparative Trial between Bexxar and Zevalin conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Comparative Trial between Bexxar and Zevalin Clinical research trials and Comparative Trial between Bexxar and Zevalin medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Comparative Trial between Bexxar and Zevalin. Comparative Trial between Bexxar and Zevalin Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Comparative Trial between Bexxar and Zevalin clinical trial. Subjects typically recieve the finest healthcare available for their Comparative Trial between Bexxar and Zevalin condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Comparative Trial between Bexxar and Zevalin  Comparative Trial between Bexxar and Zevalin
Comparative Trial between Bexxar and Zevalin
For Condition: Diffuse Large Cell Lymphoma,Follicular Lymphoma
Status: Not yet recruiting
Sponsor(s): Corixa Corporation ,
Synopsis: The primary purpose of this trial is to compare safety and efficacy between Bexxar and Zevalin.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - A histologically confirmed diagnosis of follicular lymphoma, Grade 1, 2, or 3, or diffuse large cell lymphoma concurrent with or following the diagnosis of follicular lymphoma (WHO/REAL classification). - Recurrent lymphoma after at least three qualifying therapy regimens including at least one Rituximab-containing regimen and at least one chemotherapy regimen. The patient must have either not responded or responded with a duration of response of less than 6 months to a Rituximab-containing regimen. - Performance status of at least 70% on the Karnofsky Scale and an anticipated survival of at least three months. - Bi-dimensionally measurable disease with at least one lesion measuring >= 4.0 cm2 by CT scan. - Absolute neutrophil count >=1500 cells/mm3 and a platelet count >= 100,000/mm3. - Adequate renal function (defined as serum creatinine <1.5 x upper limit of normal) and adequate hepatic function (defined as total bilirubin <1.5x upper limit of normal and AST <5x upper limit of normal). - Human Anti-Murine Antibody (HAMA) negative. Exclusion Criteria - Greater than 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens. - Hypocellular bone marrow (<=15% cellularity or marked reduction in bone marrow precursors). - Prior myeloablative therapy. - History of failed stem cell collection. - Prior radiotherapy to fields encompassing more than 25% of the blood-forming marrow. - Prior chemotherapy, biologic therapy, radiation therapy, or steroid therapy for non-Hodgkin's lymphoma (NHL) within eight weeks prior to screening procedures. Patients receiving low doses of steroids for non-neoplastic indications may enter the study (“low dose steroids” is defined as <=10 mg of prednisone or equivalent per day.) - Prior radioimmunotherapy. - Prior treatment of any non-human, particularly murine monoclonal or polyclonal antibodies for either diagnostic or therapeutic purposes. This prohibition does not extend to the chimeric monoclonal antibody, Rituximab. - Prior malignancy other than lymphoma, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for five years. - Evidence of active infection requiring IV antibiotics at the time of study enrollment. - New York Heart Association (NYHA) class III or IV heart disease or other serious illness that would preclude evaluation. - Known HIV infection. - Known brain or leptomeningeal metastases. - Acitve obstructive hydronephrosis. - Evidence of ascites observed at screening physical examination. - Known type I hypersensitivity or anaphylactic reactions to murine proteins or to any component of the Ibritumomab Tiuxetan therapeutic regimen, including Rituximab, Ibritumomab Tiuxetan, Yttrium Chloride, and Indium Chloride, or any component of the Iodine I 131 Tositumomab therapeutic regimen. - Pregnant or nursing patients.
Total Enrollment: 350
Location and Contact Information:
Additional Information:
Study ID Numbers: CCBX001-053;
Study Start Date: April 2004
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00078676
Other Diffuse Large Cell Lymphoma Studies:
1. Comparative Trial between Bexxar and Zevalin
Related Studies:
Other Diffuse Large Cell Lymphoma Clinical Trials
Other Clinical Trials
Other Clinical Trials
Comparative Trial between Bexxar and Zevalin
|
|
|
|
|
|
|
|
